Identification
- Summary
Sodium bicarbonate is a compound used for the symptomatic treatment of heartburn, acid indigestion, and upset stomach as well as the treatment of metabolic acidosis associated with conditions such as severe renal disease and circulatory insufficiency due to shock.
- Brand Names
- Alka-seltzer, Alka-seltzer Fruit Chews, Alka-seltzer Heartburn Relief, Bi-peglyte, Bibag, Bicart, Bss Ophthalmic Solution, Ceo-two, Colyte, Gavilyte-C, Gavilyte-G, Gavilyte-H and Bisacodyl, Gavilyte-N, Golytely, H.E.L.P.bicel, Hema Bp-38, Hemacart, Nulytely, Peglyte, Phoxillum, Physioneal 40, Prismasol, Zegerid, Zegerid Reformulated Aug 2006, Zegerid With Magnesium Hydroxide
- Generic Name
- Sodium bicarbonate
- DrugBank Accession Number
- DB01390
- Background
Sodium bicarbonate is a white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Sodium bicarbonate (DB01390)
- Weight
- Average: 84.0066
Monoisotopic: 83.982338573 - Chemical Formula
- CHNaO3
- Synonyms
- Baking soda
- Bicarbonate of soda
- Carbonic acid monosodium salt
- NaHCO3
- Natriumhydrogenkarbonat
- Sodio bicarbonato
- Sodium acid carbonate
- Sodium bicarbonate
- Sodium hydrogen carbonate
- Sodium hydrogencarbonate
- External IDs
- B1654
- E 500
- E-500
- E-500(II)
- E500
- INS NO.500(II)
- INS-500(II)
Pharmacology
- Indication
Sodium bicarbonate is used for the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturateprotein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Barbiturate intoxication
- Breast Cancer
- Constipation
- Dental Decay
- Duodenal Ulcer
- Dyspepsia
- Gastro-esophageal Reflux Disease (GERD)
- Gingival Bleeding
- Heartburn
- Helicobacter Infections
- Hyperkalemia
- Ischaemia
- Metabolic Acidosis
- Myocardial Infarction
- Plaque, Dental
- Pruritis of the skin
- Skin Irritation
- Upper GI Bleeding
- Upset stomach
- Zollinger-Ellison Syndrome
- Abdominal bloating
- Benign, active Gastric Ulcer
- Methyl alcohol poisoning
- Prophylaxis of Contrast-induced nephropathy
- Salicylate poisoning
- Severe Diarrhea
- Swelling of the gums
- Associated Therapies
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Intravenous sodium bicarbonate therapy increases plasma bicarbonate, buffers excess hydrogen ion concentration, raises blood pH and reverses the clinical manifestations of acidosis.
- Mechanism of action
Sodium bicarbonate is a systemic alkalizer, which increases plasma bicarbonate, buffers excess hydrogen ion concentration, and raises blood pH, thereby reversing the clinical manifestations of acidosis. It is also a urinary alkalizer, increasing the excretion of free bicarbonate ions in the urine, thus effectively raising the urinary pH. By maintaining an alkaline urine, the actual dissolution of uric acid stones may be accomplished. Sodium bicarbonate acts as an antacid and reacts chemically to neutralize or buffer existing quantities of stomach acid but has no direct effect on its output. This action results in increased pH value of stomach contents, thus providing relief of hyperacidity symptoms. [PharmGKB]
Target Actions Organism AHydrogen ions neutralizer- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcetazolamide The risk or severity of adverse effects can be increased when Acetazolamide is combined with Sodium bicarbonate. Acetophenazine Sodium bicarbonate can cause a decrease in the absorption of Acetophenazine resulting in a reduced serum concentration and potentially a decrease in efficacy. Alendronic acid The serum concentration of Alendronic acid can be decreased when it is combined with Sodium bicarbonate. Alimemazine Sodium bicarbonate can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy. Allopurinol The therapeutic efficacy of Allopurinol can be decreased when used in combination with Sodium bicarbonate. Amphetamine The serum concentration of Amphetamine can be increased when it is combined with Sodium bicarbonate. Amprenavir Sodium bicarbonate can cause a decrease in the absorption of Amprenavir resulting in a reduced serum concentration and potentially a decrease in efficacy. Asunaprevir Sodium bicarbonate can cause a decrease in the absorption of Asunaprevir resulting in a reduced serum concentration and potentially a decrease in efficacy. Atazanavir Sodium bicarbonate can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy. Beclomethasone dipropionate The bioavailability of Beclomethasone dipropionate can be decreased when combined with Sodium bicarbonate. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Take with or without food. Many different products contain sodium bicarbonate; refer to the product monograph for more specific instruction.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Active Moieties
Name Kind UNII CAS InChI Key Carbon dioxide unknown 142M471B3J 124-38-9 CURLTUGMZLYLDI-UHFFFAOYSA-N Sodium cation ionic LYR4M0NH37 17341-25-2 FKNQFGJONOIPTF-UHFFFAOYSA-N Bicarbonate ion ionic HN1ZRA3Q20 71-52-3 BVKZGUZCCUSVTD-UHFFFAOYSA-M - Product Images
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image 7.5% Sodium Bicarbonate Injection, solution 75 mg/1mL Intravenous HF Acquisition Co LLC, DBA HealthFirst 2020-01-29 Not applicable US 
8.4% Sodium Bicarbonate Injection, solution 84 mg/1mL Intravenous HF Acquisition Co. LLC, DBA HealthFirst 2018-09-01 Not applicable US 800 Sodium Bicarbonate Powder Powder, for solution 650 g / 8 L Hemodialysis Baxter Laboratories 1988-12-31 Not applicable Canada 
Bibag Powder, for solution 650 g / bag Hemodialysis Fresenius Medical Care Korea 2009-12-10 Not applicable Canada Bibag Powder, for solution 900 g / bag Hemodialysis Fresenius Medical Care Korea 2020-01-30 Not applicable Canada Bicarb Hemodial Conc 81.25gm/l Liquid 81.25 g / L Hemodialysis Bicarbolyte Corporation 1986-12-31 1998-06-08 Canada Bicarbolyte Bicar Hemodialysis Conc Liquid 72 g / L Hemodialysis Bicarbolyte Corporation 1986-12-31 1998-06-08 Canada Bicarbonate Conc Mb-330 Pwr 650mg/pck Powder 650 g / pck Hemodialysis Renal Systems, Division Of Minntech Corp. 1985-12-31 1998-11-02 Canada Bicarbonate Concentrate 4105 Liquid 80.68 g / L Hemodialysis Baxter Laboratories 1988-12-31 2002-08-01 Canada Bicarbonate Concentrate B38 Solution 80.7 g / L Hemodialysis Chief Medical Supplies Ltd 2005-07-04 Not applicable Canada - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Sodium Bicarbonate Injection, solution 84 mg/1mL Intravenous Exela Pharma Sciences, LLC 2020-09-01 Not applicable US Sodium Bicarbonate Injection, solution 84 mg/1mL Intravenous Civica 2019-08-01 Not applicable US Sodium Bicarbonate Injection 84 mg/1mL Intravenous Remedy Repack 2018-01-12 2018-03-08 US Sodium Bicarbonate Injection, solution 42 mg/1mL Intravenous Exela Pharma Sciences, LLC 2018-09-27 Not applicable US Sodium Bicarbonate Injection 84 mg/1mL Intravenous International Medication Systems, Limited 2000-06-01 Not applicable US Sodium Bicarbonate Injection, solution 42 mg/1mL Intravenous Henry Schein, Inc. 2022-01-12 Not applicable US Sodium Bicarbonate Injection, solution 42 mg/1mL Intravenous Hospira, Inc. 2020-08-26 Not applicable US Sodium Bicarbonate Injection, solution 42 mg/1mL Intravenous HF Acquisition Co LLC, DBA HealthFirst 2020-02-18 Not applicable US Sodium Bicarbonate Injection, solution 84 mg/1mL Intravenous Exela Pharma Sciences, LLC 2019-08-01 Not applicable US Sodium Bicarbonate Injection, solution 84 mg/1mL Intravenous Hospira, Inc. 2006-05-18 2009-07-01 US - Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image After Bite Advanced Liquid 50 mg/1mL Topical Adventure Ready Brands 2020-09-01 2023-12-31 US After Bite Advanced Liquid 50 mg/1mL Topical Adventure Ready Brands 2021-01-01 Not applicable US After Bite Kids Liquid 5 g/100g Topical Adventure Ready Brands 2020-09-01 Not applicable US After Bite Kids Liquid 5 g/100g Topical Tender Corporation 2014-11-26 2020-09-30 US After Bite Sensitive Liquid 5 g/100g Topical Tender Corporation 2014-11-26 Not applicable US After Bite the Itch Eraser Liquid 50 mg/1mL Topical Tender Corporation 2014-09-02 2020-09-30 US After Bite The Itch Eraser KIDS Liquid 5 g/100g Topical Tender Corporation 2014-11-25 2014-11-25 US After Bite The Itch Eraser KIDS Liquid 5 g/100g Topical Tender Corporation 2014-11-26 2014-11-26 US After Bite Wipe Swab 50 mg/1mL Topical Tender Corporation 2019-07-01 2022-09-30 US After Bite X Tech Liquid 50 mg/1000mL Topical Adventure Ready Brands 2023-01-01 Not applicable US - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image ACCUSOL 35 Sodium bicarbonate (12.9 g/L) + Calcium chloride dihydrate (0.343 g/L) + Magnesium chloride hexahydrate (0.136 g/L) + Sodium chloride (7.66 g/L) Solution บริษัท ซิลลิค ฟาร์มา จำกัด 2015-08-31 Not applicable Thailand 
ACIFREE® DOBLE ACCIÓN Sodium bicarbonate (2.13 g) + Sodium alginate (5 g) + Calcium carbonate (3.25 g) Suspension Oral LABORATORIOS DEMAC LTDA. 2019-12-03 Not applicable Colombia 
Adea Gargle Sodium bicarbonate (36.2 g/100mg) + Xylitol (5 g/100mg) Tablet, chewable Oral K2resource Co., Ltd. 2018-03-01 2018-04-01 US Adea Gargle Sodium bicarbonate (36.2 g/100mg) + Xylitol (5 g/100mg) Tablet, chewable Oral K2resource Co., Ltd. 2018-03-01 Not applicable US AGRILAX SUSPENSION Sodium bicarbonate (2.67 g) + Sodium alginate (2.5 g) Suspension Oral COLOMPACK S.A. 2012-09-03 Not applicable Colombia AGRILAX SUSPENSION Sodium bicarbonate (2.67 g) + Sodium alginate (2.5 g) Suspension Oral COLOMPACK S.A. 2012-09-03 Not applicable Colombia ALGIDROX PLUS SUSPENSION ORAL Sodium bicarbonate (2.67 g) + Sodium alginate (2.5 g) Suspension Oral COASPHARMA S.A.S. 2018-05-18 Not applicable Colombia Alka Seltzer Sodium bicarbonate (1916 mg/1) + Acetylsalicylic acid (325 mg/1) + Citric acid (1000 mg/1) Tablet, effervescent Oral Salimex, S.A. 2012-10-10 Not applicable US Alka Seltzer Sodium bicarbonate (1916 mg/1) + Acetylsalicylic acid (325 mg/1) + Citric acid (1000 mg/1) Tablet, effervescent Oral Salimex, S.A. 2012-10-10 Not applicable US Alka Seltzer Evt Sodium bicarbonate (1.916 g) + Acetylsalicylic acid (325 mg) + Citric acid (1 g) Tablet, effervescent Oral Miles Inc. Pharmaceutical Division 1977-12-31 1996-09-09 Canada - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image 7.5% Sodium Bicarbonate Sodium bicarbonate (75 mg/1mL) Injection, solution Intravenous HF Acquisition Co LLC, DBA HealthFirst 2020-01-29 Not applicable US 8.4% Sodium Bicarbonate Sodium bicarbonate (84 mg/1mL) Injection, solution Intravenous HF Acquisition Co. LLC, DBA HealthFirst 2018-09-01 Not applicable US Adea Gargle Sodium bicarbonate (36.2 g/100mg) + Xylitol (5 g/100mg) Tablet, chewable Oral K2resource Co., Ltd. 2018-03-01 2018-04-01 US Adea Gargle Sodium bicarbonate (36.2 g/100mg) + Xylitol (5 g/100mg) Tablet, chewable Oral K2resource Co., Ltd. 2018-03-01 Not applicable US All natural Saline Packets CareOne Sodium bicarbonate (700 mg/3000mg) + Sodium chloride (2300 mg/3000mg) Powder, for solution Nasal Foodhold U.S.A. 2022-01-08 Not applicable US Aqua De Folli Hair Booster Sodium bicarbonate (0.006 g/100mL) + Magnesium sulfate (0.00024 g/100mL) + Zinc sulfate, unspecified form (0.0000022 g/100mL) Liquid Topical ROKIT HEALTHCARE Inc. 2020-09-24 Not applicable US Aqua De Folli Hair Booster Mini Sodium bicarbonate (0.006 g/100mL) + Magnesium sulfate (0.00024 g/100mL) + Zinc sulfate, unspecified form (0.0000022 g/100mL) Liquid Topical ROKIT HEALTHCARE Inc. 2020-09-24 Not applicable US Aqua De Folli Hair Booster Pro Sodium bicarbonate (0.006 g/100mL) + Magnesium sulfate (0.00024 g/100mL) + Zinc sulfate, unspecified form (0.0000022 g/100mL) Liquid Topical ROKIT HEALTHCARE Inc. 2020-09-24 Not applicable US Assured Bug Bite Relief Sodium bicarbonate (5 g/100g) Liquid Topical Shanghai Weierya Daily Chemicals Factory 2015-11-10 Not applicable US Bablab Super Clean Calming Cleansing Balm Sodium bicarbonate (4.5 g/90mL) Cream Topical FICC Co., Ltd. 2021-05-01 Not applicable US
Categories
- ATC Codes
- B05CB04 — Sodium bicarbonate
- B05CB — Salt solutions
- B05C — IRRIGATING SOLUTIONS
- B05 — BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
- B — BLOOD AND BLOOD FORMING ORGANS
- Drug Categories
- Antacids
- Antacids and Adsorbents
- Bicarbonates
- Blood and Blood Forming Organs
- Blood Substitutes and Perfusion Solutions
- Carbon Compounds, Inorganic
- Carbonates
- Carbonic Acid
- Electrolyte Solutions
- Gastric Acid Lowering Agents
- Hemodialysis Solution
- I.V. Solution Additives
- Irrigating Solutions
- Salt Solutions
- Sodium Compounds
- Urinary Alkalinisers
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as organic carbonic acids. These are compounds comprising the carbonic acid functional group.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Organic carbonic acids and derivatives
- Sub Class
- Organic carbonic acids
- Direct Parent
- Organic carbonic acids
- Alternative Parents
- Carbonate salts / Organic sodium salts / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
- Substituents
- Aliphatic acyclic compound / Carbonate salt / Carbonic acid / Carbonyl group / Hydrocarbon derivative / Organic alkali metal salt / Organic oxide / Organic oxygen compound / Organic salt / Organic sodium salt
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- one-carbon compound, organic sodium salt (CHEBI:32139)
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 8MDF5V39QO
- CAS number
- 144-55-8
- InChI Key
- UIIMBOGNXHQVGW-UHFFFAOYSA-M
- InChI
- InChI=1S/CH2O3.Na/c2-1(3)4;/h(H2,2,3,4);/q;+1/p-1
- IUPAC Name
- sodium hydrogen carbonate
- SMILES
- [Na+].OC([O-])=O
References
- Synthesis Reference
Alan B. Gancy, Rustom P. Poncha, "Production of low bulk density product from sodium bicarbonate by the use of an inert gas stream." U.S. Patent US3984527, issued August, 1922.
US3984527- General References
- TITCK Product Information: ENHOŞ MEYVE TUZU (tartaric acid/sodium bicarbonate) effervescent powder [Link]
- INVIMA Product Authorization: Lua Plus Fruit Salt (simeticone/sodium bicarbonate) oral granules [Link]
- AIFA Package Leaflet: TETROFOSMINA ROTOP (sodium bicarbonate and tetrofosmin) intravenous kit [Link]
- FDA Approved Drug Products: KONVOMEP™ (omeprazole and sodium bicarbonate for oral suspension) [Link]
- External Links
- Human Metabolome Database
- HMDB0303541
- KEGG Drug
- D01203
- KEGG Compound
- C12603
- PubChem Compound
- 516892
- PubChem Substance
- 46507049
- ChemSpider
- 8609
- 36676
- ChEBI
- 32139
- ChEMBL
- CHEMBL1353
- Therapeutic Targets Database
- DAP000128
- PharmGKB
- PA451375
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Sodium_bicarbonate
- MSDS
- Download (74 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Active Not Recruiting Treatment Acute Kidney Injury (AKI) / Coronavirus Disease 2019 (COVID‑19) / COVID / Infections, Coronavirus 1 4 Active Not Recruiting Treatment Varicosities of the great saphenous vein 1 4 Completed Not Available Colonoscopy 1 4 Completed Not Available Normal Healthy Subject Population 1 4 Completed Not Available Pain of Anesthesia at Breast Biopsy 1 4 Completed Diagnostic Anatomic renal artery stenosis / Chronic Kidney Disease (CKD) / Pulmonary Cancer / Pulmonary Embolism 1 4 Completed Prevention Acute Kidney Injury (AKI) 1 4 Completed Prevention Acute Renal Failure (ARF) / End Stage Renal Disease (ESRD) / Hemodialysis Access Failure (Disorder) / Hemodialysis Catheter Infection / Hemodialysis Catheter-Associated Bacteremia / Hemodialysis Complication 1 4 Completed Prevention Contrast Induced Acute Kidney Injury 1 4 Completed Prevention Contrast media reaction / Kidney Diseases 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Alaven Pharmaceutical
- Alcon Laboratories
- American Regent
- Amphastar Pharmaceuticals
- APP Pharmaceuticals
- A-S Medication Solutions LLC
- Atlantic Biologicals Corporation
- B. Braun Melsungen AG
- C.O. Truxton Inc.
- Cardinal Health
- Claris Lifesciences Inc.
- Concord Labs
- Consolidated Medical Imaging
- Cura Pharmaceutical Co. Inc.
- Dispensing Solutions
- Fresenius Kabi AB
- General Injectables and Vaccines Inc.
- Hospira Inc.
- Humco
- Luitpold Pharmaceuticals Inc.
- Mckesson Corp.
- Mylan
- Norwich Pharmaceuticals Inc.
- Physicians Total Care Inc.
- Prasco Labs
- QOL Medical
- Sandhills Packaging Inc.
- Santarus Inc.
- Dosage Forms
Form Route Strength Powder, for solution Hemodialysis 650 g / 8 L Solution Hemodialysis 0.257 g/1000ml Liquid Topical 50 mg/1mL Liquid Topical 5 g/100g Swab Topical 50 mg/1mL Liquid Topical 50 mg/1000mL Tablet, effervescent Oral Tablet Oral 324 mg Injection, powder, for suspension Hemodialysis 750 mg Powder, for solution Intraocular Capsule Oral Liquid Topical Liquid Topical 5 g/100mL Solution Intravenous Injection Intravenous Solution Hemodialysis; Topical 8.4 g Cream Topical 4.5 g/90mL Powder Oral 100 % Powder, for solution Oral 100 g Granule Oral 460 mg/g Kit; powder, for solution; tablet, delayed release Oral Powder, for solution Hemodialysis 650 g / bag Powder, for solution Hemodialysis 900 g / bag Powder, for solution Extracorporeal 100 % Powder, for solution Hemodialysis 100 g Powder, for solution Hemodialysis 100 % Injection, powder, for solution Hemodialysis 100 g Liquid Hemodialysis 81.25 g / L Liquid Hemodialysis 72 g / L Liquid Hemodialysis 80.68 g / L Solution Hemodialysis 80.7 g / L Solution Hemodialysis 81.3 g / L Liquid Hemodialysis Solution Intravenous 0.8401 g Solution Intravenous 840 mg Solution Intravenous 0.84 g Solution Parenteral 840 mg Injection, powder, lyophilized, for solution Hemodialysis 8.125 g Solution Intravenous 840.1 mg Powder Hemodialysis 1250 g / cartridge Powder Hemodialysis 650 g / cartridge Powder Hemodialysis 720 g / cartridge Kit; powder, for solution Hemodialysis Powder, for solution Hemodialysis 750 g / cartridge Powder, for solution Hemodialysis 900 g / cartridge Powder, for solution Oral 1.685 g Solution Hemodialysis; Intravenous Solution Hemodialysis; Intravenous 0.187 g/L Granule, effervescent Oral 0.65 g Granule, effervescent Oral Granule, effervescent Oral 1.02 g/5g Granule, effervescent Oral 1.8 g / 6 g Granule, effervescent Oral 269 mg / g Concentrate; kit; solution Ophthalmic Kit; solution Intraocular Liquid Ophthalmic Liquid Intravenous Suppository Rectal Kit Intravenous Powder, for solution Nasogastric Solution Hemodialysis; Topical 6.5527 g Solution, concentrate Hemodialysis Injection, powder, lyophilized, for solution Hemodialysis Kit; powder Nasal Powder Nasal Powder, for solution Hemodialysis 650 g / pck Liquid Oral 525 mg/15mL Solution Parenteral 8.4 g Injection Intravenous 84 mg/ml Solution Intravenous 4.21 g/1000ml Liquid Oral 25 mg/1mL Injection, solution Intravenous Injection Intrathecal Injection, solution Intraperitoneal Granule, for solution Oral 64 g Granule Hemodialysis 100 g Tablet, delayed release Oral 1000 MG Suspension Oral 2.5 g Suspension Oral 325 MG/10ML Tablet, chewable Oral 187.5 MG Suspension Oral 160 MG/10ML Tablet, chewable Oral 80 MG Tablet, chewable Buccal Powder, for solution Oral 1 g/1g Powder, for solution Nasogastric; Oral Powder Topical 165 g/300g Solution Hemodialysis Kit Oral Solution Hemodialysis 66 g/l Powder 6 kg / container Powder, for solution Hemodialysis 650 g / cartridge Solution, concentrate Hemodialysis 8.4 g/100mL Solution, concentrate Intravenous 8.4 g/100mL Solution Hemodialysis 8.4 g Injection, solution Intravenous 8.4 % Powder Oral 1000 mg/1g Granule Oral Kit; solution; suspension Oral Tablet Topical 60 g/100g Tablet Transmucosal Injection Suspension Oral Solution Intravenous 0.84 g/10ml Powder, for solution Oral 13.125 g Powder, for solution Oral 13.125 G Injection, solution, concentrate Oral Injection, solution Hemodialysis; Intravenous Solution Intravenous 1.68 g Injection, solution, concentrate Parenteral Capsule, delayed release Oral Kit; solution Intraocular; Irrigation Injection, solution Intravenous 0.2 g/5mL Tablet Oral For suspension Oral Powder, for suspension Oral Liquid; mouthwash Oral Paste Dental Injection, solution Intramuscular 84 mg/1mL Powder Oral 238.33 g Solution Intraperitoneal Powder Oral Powder, for solution Oral Solution Hemodialysis; Intravenous 0.27 g/l Kit Hemodialysis Solution Intravenous Injection Intravenous Solution Hemodialysis 0.257 g/l Lotion Topical Kit Dental Liquid Oral Solution Oral Powder, for solution Oral 56.6 g Granule, effervescent Oral 1.415 g Powder, for solution Nasal Kit; powder, for solution Nasal Kit; powder; solution Nasal Injection, solution Intravenous Tablet Parenteral Injection, solution Parenteral 1 MEQ/ML Injection, solution Parenteral 1.4 % Injection, solution Parenteral 5 % Injection, solution Parenteral 7.5 % Injection, solution Parenteral 8.4 G/100MG Injection, solution Parenteral 8.4 % Injection, solution, concentrate Intravenous 10 MEQ/10ML Injection, solution, concentrate Intravenous 1 MEQ/ML Injection, solution Parenteral Injection, solution, concentrate Intravenous Injection Intravenous 84 mg/1mL Injection Parenteral 42 mg/1mL Injection Parenteral 84 mg/1mL Injection, solution Intravenous 1 meq/1mL Injection, solution Intravenous 42 mg/1mL Injection, solution Intravenous 44.6 meq/50mL Injection, solution Intravenous 75 mg/1mL Injection, solution Intravenous 84 mg/1mL Powder Oral; Topical 100 % Solution Intravenous 42 mg/1mL Solution Intravenous 84 mg/1mL Solution Parenteral 84 mg/1mL Tablet Tablet 500 MG Tablet Oral 650 mg/1 Tablet, orally disintegrating Oral 650 mg/1 Tablet Oral 648 mg/1 Tablet, soluble Oral 648 mg/1 Tablet Oral 325 mg/1 Tablet, soluble Oral 324 mg/1 Liquid Intravenous 50 mg / mL Solution Intravenous 5 g / 100 mL Powder Oral 2.52 g/2.52g Powder Oral 2.6 g/2.6g Powder Oral 2.616 g/2.616g Capsule Oral 500 mg Powder, for solution Hemodialysis 672 g / pck Powder Hemodialysis 650 g / pck Liquid Intravenous 42 mg / mL Liquid Intravenous 75 mg / mL Liquid Intravenous 84 mg / mL Solution Intravenous 4200 mg / 50 mL Solution Intravenous 840 mg / 10 mL Solution Intravenous 75 mg / mL Injection Intravenous 8.4 g/100ml Solution Intravenous 42 mg / mL Solution Intravenous 84 mg / mL Injection Intravenous 8.4 % w/v Injection Intravenous 4.2 % w/v Tablet Oral 300 mg Tablet Oral 600 mg Powder Hemodialysis 650 g / sachet Powder Hemodialysis Powder, for solution Hemodialysis 1100 g / cartridge Powder, for solution Hemodialysis 760 g / cartridge Solution Extracorporeal Solution Extracorporeal Solution Capsule Oral Powder, for solution Hemodialysis Injection, powder, for solution Intravenous Kit; powder, for solution Intravenous Cream Topical 50 mg/1g Capsule, gelatin coated Oral Injection, solution Intravenous 840 mg/10ml Granule, for solution Oral Granule, effervescent Oral 0.72 g Tablet Oral 200 mg Tablet Oral 250 mg Kit Nasal Granule, for solution Nasal Tablet, chewable Oral Syrup Syrup 50 mg/5ml Suspension Tablet 300 mg Solution 0.6 g/5mL Tablet, sugar coated Oral Powder Solution 50 mg/5ml Tablet 650 mg Solution Intravenous 75 mg/1ml Tablet - Prices
Unit description Cost Unit Golytely 236 gm Solution 28.0USD bottle Colyte 240 gm Solution 26.0USD bottle Golytely 227.1 gm Solution Packet 21.85USD packet Colyte-Flavored 240 gm Solution 18.17USD bottle Elliotts b solution ampule 4.71USD ml Sodium bicarb 4.2% vial 1.45USD ml Neut 4% vial 0.92USD ml Bss plus eye solution 0.2USD ml Sodium bicarb 650 mg tablet 0.07USD tablet Antacid 650 mg tablet 0.05USD tablet Antacid 325 mg tablet 0.04USD tablet Sodium bicarb 325 mg tablet 0.04USD tablet Sodium bicarb 7.5% vial 0.04USD ml Sodium bicarbonate powder 0.03USD g Sodium bicarb 8.4% vial 0.02USD ml Sodium bicarbonate 5% inj 0.02USD ml Colyte with flavor packets 0.01USD ml DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US6489346 No 2002-12-03 2016-07-16 US US6699885 No 2004-03-02 2016-07-16 US USRE45198 No 2014-10-14 2016-07-16 US US6645988 No 2003-11-11 2016-07-16 US US7399772 No 2008-07-15 2016-07-16 US US5945449 No 1999-08-31 2017-10-31 US US7300674 No 2007-11-27 2023-03-04 US US7291324 No 2007-11-06 2022-10-22 US US5840737 No 1998-11-24 2016-07-15 US US6780882 No 2004-08-24 2016-07-15 US US7084130 No 2006-08-01 2021-11-29 US US10751333 No 2019-07-16 2039-07-16 US US11103492 No 2019-07-16 2039-07-16 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) Decomposes around 50 °C Not Available water solubility 1E+005 mg/L (at 25 °C) MERCK INDEX (1996) pKa 6.3 Not Available - Predicted Properties
Property Value Source Water Solubility 764.0 mg/mL ALOGPS logP -0.06 ALOGPS logP 0.25 Chemaxon logS 0.96 ALOGPS pKa (Strongest Acidic) 3.5 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 60.36 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 20.34 m3·mol-1 Chemaxon Polarizability 3.86 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9292 Blood Brain Barrier + 0.936 Caco-2 permeable - 0.5321 P-glycoprotein substrate Non-substrate 0.8785 P-glycoprotein inhibitor I Non-inhibitor 0.9903 P-glycoprotein inhibitor II Non-inhibitor 0.9931 Renal organic cation transporter Non-inhibitor 0.9563 CYP450 2C9 substrate Non-substrate 0.8326 CYP450 2D6 substrate Non-substrate 0.9017 CYP450 3A4 substrate Non-substrate 0.8144 CYP450 1A2 substrate Non-inhibitor 0.9053 CYP450 2C9 inhibitor Non-inhibitor 0.9337 CYP450 2D6 inhibitor Non-inhibitor 0.9401 CYP450 2C19 inhibitor Non-inhibitor 0.9461 CYP450 3A4 inhibitor Non-inhibitor 0.9774 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9911 Ames test Non AMES toxic 0.9285 Carcinogenicity Non-carcinogens 0.5181 Biodegradation Ready biodegradable 0.9636 Rat acute toxicity 1.9204 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9596 hERG inhibition (predictor II) Non-inhibitor 0.9866
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Yes
Neutralizer
References
- Nudel DB, Peterson BJ, Buckley BJ, Kaplan NA, Weinhaouse E, Gootman N: Comparative effects of bicarbonate and dichloroacetate in newborn swine with hypoxic lactic acidosis. Dev Pharmacol Ther. 1990;15(2):86-93. [Article]
- Roderick P, Willis NS, Blakeley S, Jones C, Tomson C: Correction of chronic metabolic acidosis for chronic kidney disease patients. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD001890. [Article]
- Balali-Mood M, Balali-Mood K: Neurotoxic disorders of organophosphorus compounds and their managements. Arch Iran Med. 2008 Jan;11(1):65-89. [Article]
- Vaughan-Jones RD, Spitzer KW: Role of bicarbonate in the regulation of intracellular pH in the mammalian ventricular myocyte. Biochem Cell Biol. 2002;80(5):579-96. [Article]
- Levraut J, Giunti C, Ciebiera JP, de Sousa G, Ramhani R, Payan P, Grimaud D: Initial effect of sodium bicarbonate on intracellular pH depends on the extracellular nonbicarbonate buffering capacity. Crit Care Med. 2001 May;29(5):1033-9. [Article]
Transporters
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Sodium:bicarbonate symporter activity
- Specific Function
- Electrogenic sodium/bicarbonate cotransporter with a Na(+):HCO3(-) stoichiometry varying from 1:2 to 1:3. May regulate bicarbonate influx/efflux at the basolateral membrane of cells and regulate in...
- Gene Name
- SLC4A4
- Uniprot ID
- Q9Y6R1
- Uniprot Name
- Electrogenic sodium bicarbonate cotransporter 1
- Molecular Weight
- 121459.38 Da
References
- Bernardo AA, Bernardo CM, Espiritu DJ, Arruda JA: The sodium bicarbonate cotransporter: structure, function, and regulation. Semin Nephrol. 2006 Sep;26(5):352-60. [Article]
- Kurtz I, Petrasek D, Tatishchev S: Molecular mechanisms of electrogenic sodium bicarbonate cotransport: structural and equilibrium thermodynamic considerations. J Membr Biol. 2004 Jan 15;197(2):77-90. [Article]
- Soleimani M: Functional and molecular properties of Na+:HCO-3 cotransporters (NBC). Minerva Urol Nefrol. 2003 Jun;55(2):131-40. [Article]
- Soleimani M: Na+:HCO3- cotransporters (NBC): expression and regulation in the kidney. J Nephrol. 2002 Mar-Apr;15 Suppl 5:S32-40. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Sodium:bicarbonate symporter activity
- Specific Function
- Electroneutral sodium- and bicarbonate-dependent cotransporter with a Na(+):HCO3(-) 1:1 stoichiometry. Regulates intracellular pH and may play a role in bicarbonate salvage in secretory epithelia. ...
- Gene Name
- SLC4A7
- Uniprot ID
- Q9Y6M7
- Uniprot Name
- Sodium bicarbonate cotransporter 3
- Molecular Weight
- 136042.595 Da
References
- Bernardo AA, Bernardo CM, Espiritu DJ, Arruda JA: The sodium bicarbonate cotransporter: structure, function, and regulation. Semin Nephrol. 2006 Sep;26(5):352-60. [Article]
- Kurtz I, Petrasek D, Tatishchev S: Molecular mechanisms of electrogenic sodium bicarbonate cotransport: structural and equilibrium thermodynamic considerations. J Membr Biol. 2004 Jan 15;197(2):77-90. [Article]
- Soleimani M: Functional and molecular properties of Na+:HCO-3 cotransporters (NBC). Minerva Urol Nefrol. 2003 Jun;55(2):131-40. [Article]
- Soleimani M: Na+:HCO3- cotransporters (NBC): expression and regulation in the kidney. J Nephrol. 2002 Mar-Apr;15 Suppl 5:S32-40. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Sodium:bicarbonate symporter activity
- Specific Function
- Mediates electroneutral sodium- and carbonate-dependent chloride-HCO3(-) exchange with a Na(+):HCO3(-) stoichiometry of 2:1. Plays a major role in pH regulation in neurons. May be involved in cell ...
- Gene Name
- SLC4A8
- Uniprot ID
- Q2Y0W8
- Uniprot Name
- Electroneutral sodium bicarbonate exchanger 1
- Molecular Weight
- 122936.66 Da
References
- Bernardo AA, Bernardo CM, Espiritu DJ, Arruda JA: The sodium bicarbonate cotransporter: structure, function, and regulation. Semin Nephrol. 2006 Sep;26(5):352-60. [Article]
- Kurtz I, Petrasek D, Tatishchev S: Molecular mechanisms of electrogenic sodium bicarbonate cotransport: structural and equilibrium thermodynamic considerations. J Membr Biol. 2004 Jan 15;197(2):77-90. [Article]
- Soleimani M: Functional and molecular properties of Na+:HCO-3 cotransporters (NBC). Minerva Urol Nefrol. 2003 Jun;55(2):131-40. [Article]
- Soleimani M: Na+:HCO3- cotransporters (NBC): expression and regulation in the kidney. J Nephrol. 2002 Mar-Apr;15 Suppl 5:S32-40. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Sodium:bicarbonate symporter activity
- Specific Function
- Mediates sodium- and bicarbonate-dependent electrogenic sodium bicarbonate cotransport, with a Na(+):HCO3(-) stoichiometry of 2:1. May have a housekeeping function in regulating the pH of tissues i...
- Gene Name
- SLC4A5
- Uniprot ID
- Q9BY07
- Uniprot Name
- Electrogenic sodium bicarbonate cotransporter 4
- Molecular Weight
- 126254.04 Da
References
- Bernardo AA, Bernardo CM, Espiritu DJ, Arruda JA: The sodium bicarbonate cotransporter: structure, function, and regulation. Semin Nephrol. 2006 Sep;26(5):352-60. [Article]
- Kurtz I, Petrasek D, Tatishchev S: Molecular mechanisms of electrogenic sodium bicarbonate cotransport: structural and equilibrium thermodynamic considerations. J Membr Biol. 2004 Jan 15;197(2):77-90. [Article]
- Soleimani M: Functional and molecular properties of Na+:HCO-3 cotransporters (NBC). Minerva Urol Nefrol. 2003 Jun;55(2):131-40. [Article]
- Soleimani M: Na+:HCO3- cotransporters (NBC): expression and regulation in the kidney. J Nephrol. 2002 Mar-Apr;15 Suppl 5:S32-40. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Sodium:bicarbonate symporter activity
- Specific Function
- Electrogenic sodium/bicarbonate cotransporter in exchange for intracellular chloride. Plays an important role in regulating intracellular pH (By similarity).
- Gene Name
- SLC4A10
- Uniprot ID
- Q6U841
- Uniprot Name
- Sodium-driven chloride bicarbonate exchanger
- Molecular Weight
- 125945.115 Da
References
- Bernardo AA, Bernardo CM, Espiritu DJ, Arruda JA: The sodium bicarbonate cotransporter: structure, function, and regulation. Semin Nephrol. 2006 Sep;26(5):352-60. [Article]
- Kurtz I, Petrasek D, Tatishchev S: Molecular mechanisms of electrogenic sodium bicarbonate cotransport: structural and equilibrium thermodynamic considerations. J Membr Biol. 2004 Jan 15;197(2):77-90. [Article]
- Soleimani M: Functional and molecular properties of Na+:HCO-3 cotransporters (NBC). Minerva Urol Nefrol. 2003 Jun;55(2):131-40. [Article]
- Soleimani M: Na+:HCO3- cotransporters (NBC): expression and regulation in the kidney. J Nephrol. 2002 Mar-Apr;15 Suppl 5:S32-40. [Article]
Drug created at July 08, 2007 16:59 / Updated at January 28, 2023 12:29